Treatment timing shifts the benefits of short and long antibiotic treatment over infection
暂无分享,去创建一个
[1] R. Woods,et al. Why is preventing antibiotic resistance so hard? Analysis of failed resistance management , 2020, Evolution, medicine, and public health.
[2] D. Sim,et al. Effect of drug dose and timing of treatment on the emergence of drug resistance in vivo in a malaria model , 2020, bioRxiv.
[3] R. Ahmed,et al. Dependence of CD8 T Cell Response upon Antigen Load During Primary Infection , 2019, Bulletin of Mathematical Biology.
[4] Kevin B. Wood,et al. Antibiotics can be used to contain drug-resistant bacteria by maintaining sufficiently large sensitive populations , 2019, PLoS biology.
[5] S. Cosgrove,et al. Rethinking How Antibiotics Are Prescribed: Incorporating the 4 Moments of Antibiotic Decision Making Into Clinical Practice , 2019, JAMA.
[6] M. Singer,et al. Antibiotics for Sepsis-Finding the Equilibrium. , 2018, JAMA.
[7] Michael Lawrence Barnett,et al. The distribution of antibiotic use and its association with antibiotic resistance , 2018, bioRxiv.
[8] R. Antia,et al. Within-host competition can delay evolution of drug resistance in malaria , 2018, PLoS Biology.
[9] S. Bonhoeffer,et al. Antibiotic treatment protocols revisited: the challenges of a conclusive assessment by mathematical modelling , 2018, bioRxiv.
[10] L. Leibovici,et al. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial , 2018, JAMA.
[11] Matthew S. Walters,et al. Rapid Growth of Uropathogenic Escherichia coli during Human Urinary Tract Infection , 2018, mBio.
[12] Merle L. Gilbert,et al. Mitigating the Impact of Antibacterial Drug Resistance through Host-Directed Therapies: Current Progress, Outlook, and Challenges , 2018, mBio.
[13] David J. Moquin,et al. Influenza Virus Infection Model With Density Dependence Supports Biphasic Viral Decay , 2018, bioRxiv.
[14] V. V. Ganusov,et al. Defining Kinetic Properties of HIV-Specific CD8+ T-Cell Responses in Acute Infection , 2017, bioRxiv.
[15] Daniel J. Wilson,et al. The distribution of bacterial doubling times in the wild , 2017, bioRxiv.
[16] B. Levin,et al. Phagocytes, Antibiotics, and Self-Limiting Bacterial Infections. , 2017, Trends in microbiology.
[17] A. Casadevall,et al. What Is a Host? Attributes of Individual Susceptibility , 2017, Infection and Immunity.
[18] N. Roberts,et al. Short-course versus long-course oral antibiotic treatment for infections treated in outpatient settings: a review of systematic reviews , 2017, Family practice.
[19] Christian Munck,et al. Prediction of antibiotic resistance: time for a new preclinical paradigm? , 2017, Nature Reviews Microbiology.
[20] Lucy Yardley,et al. The antibiotic course has had its day , 2017, British Medical Journal.
[21] R. Frenck,et al. Developing and utilizing controlled human models of infection. , 2017, Vaccine.
[22] D. Andersson,et al. Environmental and genetic modulation of the phenotypic expression of antibiotic resistance , 2017, FEMS microbiology reviews.
[23] Sebastian Bonhoeffer,et al. Assessing the public health impact of tolerance-based therapies with mathematical models , 2016, bioRxiv.
[24] B. Spellberg. The New Antibiotic Mantra-"Shorter Is Better". , 2016, JAMA internal medicine.
[25] Erida Gjini,et al. Integrating Antimicrobial Therapy with Host Immunity to Fight Drug-Resistant Infections: Classical vs. Adaptive Treatment , 2016, PLoS Comput. Biol..
[26] M. Wootton,et al. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis , 2016, British Medical Journal.
[27] Troy Day,et al. Does High-Dose Antimicrobial Chemotherapy Prevent the Evolution of Resistance? , 2016, PLoS Comput. Biol..
[28] T. Cohen,et al. How competition governs whether moderate or aggressive treatment minimizes antibiotic resistance , 2015, bioRxiv.
[29] Rustom Antia,et al. Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination , 2015, Proceedings of the National Academy of Sciences.
[30] Vitaly V. Ganusov,et al. Mathematical modeling provides kinetic details of the human immune response to vaccination , 2015, Front. Cell. Infect. Microbiol..
[31] M. Webber,et al. Molecular mechanisms of antibiotic resistance , 2014, Nature Reviews Microbiology.
[32] Troy Day,et al. The path of least resistance: aggressive or moderate treatment? , 2014, Proceedings of the Royal Society B: Biological Sciences.
[33] Carl T. Bergstrom,et al. Timing of antimicrobial use influences the evolution of antimicrobial resistance during disease epidemics , 2014, Evolution, medicine, and public health.
[34] Peter Ankomah,et al. Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections , 2014, Proceedings of the National Academy of Sciences.
[35] Alan S. Perelson,et al. Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study , 2014, PLoS Comput. Biol..
[36] Stephen P. Diggle,et al. Targeting virulence: can we make evolution-proof drugs? , 2014, Nature Reviews Microbiology.
[37] P. Rohani,et al. Time and dose-dependent risk of pneumococcal pneumonia following influenza: a model for within-host interaction between influenza and Streptococcus pneumoniae , 2013, Journal of The Royal Society Interface.
[38] Troy Day,et al. Aggressive Chemotherapy and the Selection of Drug Resistant Pathogens , 2013, PLoS pathogens.
[39] David L. Smith,et al. “One-Size-Fits-All”? Optimizing Treatment Duration for Bacterial Infections , 2012, PloS one.
[40] David S Schneider,et al. Tracing Personalized Health Curves during Infections , 2011, PLoS biology.
[41] Troy Day,et al. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy , 2011, Proceedings of the National Academy of Sciences.
[42] Bala Hota,et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] P. Hawkey,et al. The changing epidemiology of resistance. , 2009, The Journal of antimicrobial chemotherapy.
[44] D. Hughes,et al. Interplay in the Selection of Fluoroquinolone Resistance and Bacterial Fitness , 2009, PLoS pathogens.
[45] B. Levin,et al. Functional relationship between bacterial cell density and the efficacy of antibiotics. , 2009, The Journal of antimicrobial chemotherapy.
[46] B. Levin,et al. Exploring the role of the immune response in preventing antibiotic resistance. , 2009, Journal of theoretical biology.
[47] David S Schneider,et al. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases , 2008, Nature Reviews Immunology.
[48] O. Cars,et al. Optimizing drug exposure to minimize selection of antibiotic resistance. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[49] C. Weenink,et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study , 2006, BMJ : British Medical Journal.
[50] I. Matic,et al. Evolution of mutation rates in bacteria , 2006, Molecular microbiology.
[51] Matthew H. Samore,et al. Antimicrobial Resistance Determinants and Future Control , 2005, Emerging infectious diseases.
[52] H. Goossens,et al. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study , 2005, The Lancet.
[53] S. Levy,et al. Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.
[54] Roland R. Regoes,et al. Pharmacodynamic Functions: a Multiparameter Approach to the Design of Antibiotic Treatment Regimens , 2004, Antimicrobial Agents and Chemotherapy.
[55] John D Loike,et al. A critical concentration of neutrophils is required for effective bacterial killing in suspension , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[56] Alan S. Perelson,et al. Recruitment Times, Proliferation, and Apoptosis Rates during the CD8+ T-Cell Response to Lymphocytic Choriomeningitis Virus , 2001, Journal of Virology.
[57] I. Gould. A review of the role of antibiotic policies in the control of antibiotic resistance. , 1999, The Journal of antimicrobial chemotherapy.
[58] A S Perelson,et al. Modeling and optimization of populations subject to time-dependent mutation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[59] Rustom Antia,et al. Within-Host Population Dynamics and the Evolution and Maintenance of Microparasite Virulence , 1994, The American Naturalist.
[60] J. McHutchison,et al. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. , 1991, Gastroenterology.
[61] J. Mcgowan,et al. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. , 1983, Reviews of infectious diseases.
[62] P. Ehrlich. Address in Pathology, ON CHEMIOTHERAPY , 1913, British medical journal.
[63] Frederick R Adler,et al. An accurate two-phase approximate solution to an acute viral infection model , 2010, Journal of mathematical biology.
[64] Lurias,et al. MUTATIONS OF BACTERIA FROM VIRUS SENSITIVITY TO VIRUS RESISTANCE’-’ , 2003 .